CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human…
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug…
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO…
Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other…
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
Phio to present a clinical study progress update on their lead clinical candidate, PH-762Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024)…
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic…
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to…
Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDTCAMBRIDGE, MA / ACCESSWIRE /…
Halifax, Nova Scotia--(Newsfile Corp. - May 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…